HUMACYTE ($HUMA) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.09 per share, beating estimates of -$0.12 by $0.03. The company also reported revenue of $500,000, missing estimates of $1,484,273 by $-984,273.
You can see Quiver Quantitative's $HUMA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HUMACYTE Hedge Fund Activity
We have seen 74 institutional investors add shares of HUMACYTE stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANTIPODES PARTNERS LTD added 5,712,102 shares (+49039.3%) to their portfolio in Q1 2026, for an estimated $3,465,532
- MILLENNIUM MANAGEMENT LLC added 1,485,152 shares (+129.5%) to their portfolio in Q4 2025, for an estimated $1,426,488
- BLACKROCK, INC. added 1,443,324 shares (+14.6%) to their portfolio in Q4 2025, for an estimated $1,386,312
- BNP PARIBAS FINANCIAL MARKETS added 1,009,097 shares (+1100.0%) to their portfolio in Q4 2025, for an estimated $969,237
- VANGUARD GROUP INC added 896,916 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $861,487
- CITADEL ADVISORS LLC added 673,479 shares (+75.4%) to their portfolio in Q4 2025, for an estimated $646,876
- GEODE CAPITAL MANAGEMENT, LLC added 624,220 shares (+20.2%) to their portfolio in Q4 2025, for an estimated $599,563
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HUMACYTE Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/09/2026
- D. Boral Capital issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for HUMACYTE, check out Quiver Quantitative's $HUMA forecast page.
HUMACYTE Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 6 analysts offer price targets for $HUMA in the last 6 months, with a median target of $1.25.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $3.0 on 04/28/2026
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 04/28/2026
- Matt Miksic from Barclays set a target price of $1.5 on 04/08/2026
- Bruce D. Jackson from Benchmark set a target price of $1.0 on 03/31/2026
- Joshua Jennings from TD Cowen set a target price of $1.0 on 03/30/2026
- Allison Bratzel from Piper Sandler set a target price of $1.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
